News & Updates

For patients with proximal advanced gastric cancer (AGC), proximal gastrectomy (PG) appears to be a reasonable treatment option, particularly for those with small tumours, a recent study has found.

Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

The use of spleen pull-out lymph node dissection in the splenic hilum is both safe and feasible for patients with gastric cancer undergoing radical gastrectomy, a recent study has found.

In patients with metastatic colorectal cancer (mCRC), using trifluridine/tipiracil with bevacizumab is a safe and effective treatment for refractory disease, a recent study has found.

Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.